India Glycols Announces Senior Management Realignment; Akshay Bansal Appointed Executive Director at Ennature Bio Pharma
India Glycols Limited (IGL) has announced a key management restructuring as part of its ongoing corporate reorganization. In a regulatory filing under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company informed the stock exchanges about changes in its Senior Management Personnel (SMP) and a leadership appointment at its wholly owned subsidiary, Ennature Bio Pharma Limited (EBL).
Akshay Bansal Ceases to be Senior Management Personnel of India Glycols
According to the filing, Akshay Bansal, who was serving as Head – Sales & Marketing, Ennature Biopharma Division at India Glycols Limited, has been transferred to Ennature Bio Pharma Limited.
As a result of this transfer, Akshay Bansal ceased to be a Senior Management Personnel (SMP) of India Glycols Limited with effect from the close of business hours on July 30, 2026.
Appointed Executive Director at Ennature Bio Pharma
Following the transfer, the Board of Directors of Ennature Bio Pharma Limited approved the appointment of Akshay Bansal (DIN: 11836049) as an Additional Director (Executive Director) and Key Managerial Personnel (KMP) at its board meeting held on July 31, 2026.
Appointment Details
- Appointee: Akshay Bansal
- DIN: 11836049
- Designation: Additional Director (Executive Director) and Key Managerial Personnel (KMP)
- Company: Ennature Bio Pharma Limited
- Effective Date: July 31, 2026
- Proposed Tenure: Five consecutive years, from July 31, 2026, to July 30, 2031
- Approval Required: Subject to approval by the shareholders of Ennature Bio Pharma Limited.
Regulatory Compliance
The company also confirmed that Akshay Bansal is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India (SEBI) or any other regulatory authority, in accordance with applicable listing requirements.
Part of Ongoing Corporate Restructuring
The management realignment forms part of the Scheme of Arrangement involving:
- India Glycols Limited
- Ennature Bio Pharma Limited
- IGL Spirits Limited
The executive transition is intended to align the leadership structure with the proposed corporate reorganization and follows the observation letters issued by the National Stock Exchange of India Limited (NSE) and BSE Limited in relation to the scheme.